In line with previous reports, we found that E-cadherin expression was significantly reduced in prostate cancer and we observed a negative correlation between the expression of both E-cadherin and DSG2 and serum PSA concentration, Gleason score, and pathological stage. This evidence concerns the gene DSG2 and prostate carcinoma.